SCHEMBL10033709

SCHEMBL10033709

CC(C)(C)C1=CC(C(C)(C)C)OC1=O

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.47
LMNA P02545 1/20 0.47
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
ATM Q13315 2/20 0.36
MCL1 Q07820 1/20 0.36
CES2 O00748 1/20 0.33
PKM P14618 1/20 0.33
HPGD P15428 1/20 0.33
CES1 P23141 1/20 0.33
MPI P34949 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14183118 0.76 USP2 (0.49) USP2LMNA
SCHEMBL14564028 0.76 USP2 (0.49) USP2LMNA
SCHEMBL14269887 0.76 ALDH1A1 (0.39) USP2LMNAALDH1A1MAPTATM
SCHEMBL11961374 0.76 ALDH1A1 (0.39) USP2LMNAALDH1A1MAPTATM
SCHEMBL15677121 0.76 ALDH1A1 (0.39) USP2LMNAALDH1A1MAPTATM
SCHEMBL9968974 0.71 ALDH1A1 (0.33) ALDH1A1MAPTATMMCL1CES2
SCHEMBL18425764 0.60 ALDH1A1 (0.39) ALDH1A1MAPTATMMCL1CES2
SCHEMBL2664153 0.59 USP2 (0.34) USP2LMNA
SCHEMBL19069350 0.59 USP2 (0.34) USP2LMNA
SCHEMBL21652146 0.59 ATM (0.50) ALDH1A1MAPTATMMCL1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487545-B2 Fused ring-containing oxazolidinones antibiotics Xuanzhu Pharma Co., Ltd. (CN) 2016-11-08 US disclosed
US-9359344-B2 Biaryl heterocycle substituted oxazolidinone antibacterial agents Xuanzhu Pharma Co., Ltd. (CN) 2016-06-07 US disclosed
US-20140243288-A1 FUSED RING-CONTAINING OXAZOLIDINONES ANTIBIOTICS Xuanzhu Pharma Co., Ltd. (CN) 2014-08-28 US disclosed
US-20140235584-A1 BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS Xuanzhu Pharma Co., Ltd. (CN) 2014-08-21 US disclosed
US-8124772-B2 Intermediate products for producing oxazolidinone-quinolone hybrids Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2012-02-28 US disclosed
US-20090306389-A1 Intermediate products for producing oxazolidinone-quinolone hybrids MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2009-12-10 US disclosed
US-7557214-B2 Intermediate products for producing oxazolidinone-quinolone hybrids Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2009-07-07 US disclosed
US-20070004769-A1 Intermediate products for producing oxazolidinone-quinolone hybrids MORPHOCHEM AKTIEGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306389-A1 Intermediate products for producing oxazolidinone-quinolone hybrids OXA1L, NQO1, NQO2 USP2 4087/4885LMNA 2441/4885ALDH1A1 1021/4885
US-20070004769-A1 Intermediate products for producing oxazolidinone-quinolone hybrids OXA1L, NQO1, NQO2 USP2 4087/4885LMNA 2441/4885ALDH1A1 1021/4885
US-20140235584-A1 BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS OXA1L, CYP2C19, CBR3 USP2 4499/4885LMNA 3145/4885ALDH1A1 721/4885
US-20140243288-A1 FUSED RING-CONTAINING OXAZOLIDINONES ANTIBIOTICS OXA1L, O60361, OXER1 USP2 4256/4885LMNA 3893/4885ALDH1A1 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.